INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39001, 1847, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39002, 2065, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39003, 2237, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39004, 2407, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39005, 2881, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39006, 2911, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39007, 3528, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39008, 3721, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39009, 3966, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39010, 4673, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39011, 4800, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39012, 5132, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39013, 5484, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39014, 5752, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39015, 6247, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39016, 6752, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39017, 7342, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39018, 7415, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39019, 8050, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39020, 8248, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39021, 9266, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39022, 10046, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39023, 12037, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39024, 12050, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39025, 12293, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39026, 12306, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39027, 13365, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39028, 13367, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39029, 13418, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39030, 13633, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39031, 14386, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39032, 14869, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39033, 15425, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39034, 15470, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39035, 15471, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39036, 15474, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39037, 15762, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39038, 15938, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39039, 16198, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39040, 16392, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39041, 17046, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39042, 17124, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39043, 17289, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39044, 17408, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39045, 17735, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39046, 18492, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39047, 20510, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39048, 25721, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39049, 26433, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39050, 26519, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39051, 30005, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39052, 30230, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39053, 30309, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39054, 30370, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39055, 30379, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39056, 30414, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39057, 30577, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39058, 30650, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39059, 30678, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39060, 30679, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39061, 30683, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39062, 30836, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39063, 31014, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39064, 31032, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39065, 31483, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39066, 31484, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39067, 31596, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39068, 31769, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39069, 31808, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39070, 31815, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39071, 31930, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39072, 31931, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39073, 31946, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39074, 31975, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39075, 31987, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39076, 32008, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39077, 32145, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39078, 32174, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39079, 32182, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39080, 32214, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39081, 32221, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39082, 33747, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39083, 33824, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39084, 33882, 'Cholecalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39085, 66, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39086, 360, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39087, 1555, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39088, 1847, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39089, 2065, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39090, 2237, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39091, 2407, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39092, 2881, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39093, 2911, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39094, 3528, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39095, 3721, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39096, 3966, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39097, 4673, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39098, 4800, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39099, 5132, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39100, 5484, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39101, 5752, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39102, 6247, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39103, 6752, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39104, 7342, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39105, 7415, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39106, 8050, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39107, 8248, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39108, 9266, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39109, 10046, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39110, 12037, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39111, 12050, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39112, 12293, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39113, 12306, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39114, 13365, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39115, 13367, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39116, 13418, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39117, 13633, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39118, 14386, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39119, 14869, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39120, 15425, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39121, 15470, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39122, 15471, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39123, 15474, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39124, 15762, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39125, 15938, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39126, 16198, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39127, 16392, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39128, 17046, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39129, 17124, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39130, 17289, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39131, 17408, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39132, 17735, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39133, 18492, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39134, 20510, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39135, 25721, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39136, 26433, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39137, 26519, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39138, 30005, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39139, 30230, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39140, 30309, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39141, 30370, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39142, 30379, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39143, 30414, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39144, 30577, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39145, 30650, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39146, 30678, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39147, 30679, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39148, 30683, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39149, 30836, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39150, 31014, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39151, 31032, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39152, 31483, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39153, 31484, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39154, 31596, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39155, 31769, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39156, 31808, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39157, 31815, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39158, 31930, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39159, 31931, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39160, 31946, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39161, 31975, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39162, 31987, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39163, 32008, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39164, 32145, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39165, 32174, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39166, 32182, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39167, 32214, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39168, 32221, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39169, 33747, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39170, 33824, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39171, 33882, 'Cholecalciferol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39172, 66, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39173, 360, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39174, 1555, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39175, 1847, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39176, 2065, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39177, 2237, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39178, 2407, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39179, 2881, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39180, 2911, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39181, 3528, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39182, 3721, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39183, 3966, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39184, 4673, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39185, 4800, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39186, 5132, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39187, 5484, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39188, 5752, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39189, 6247, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39190, 6752, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39191, 7342, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39192, 7415, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39193, 8050, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39194, 8248, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39195, 9266, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39196, 10046, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39197, 12037, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39198, 12050, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39199, 12293, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39200, 12306, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39201, 13365, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39202, 13367, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39203, 13418, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39204, 13633, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39205, 14386, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39206, 14869, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39207, 15425, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39208, 15470, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39209, 15471, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39210, 15474, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39211, 15762, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39212, 15938, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39213, 16198, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39214, 16392, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39215, 17046, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39216, 17124, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39217, 17289, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39218, 17408, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39219, 17735, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39220, 18492, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39221, 20510, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39222, 25721, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39223, 26433, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39224, 26519, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39225, 30005, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39226, 30230, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39227, 30309, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39228, 30370, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39229, 30379, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39230, 30414, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39231, 30577, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39232, 30650, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39233, 30678, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39234, 30679, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39235, 30683, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39236, 30836, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39237, 31014, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39238, 31032, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39239, 31483, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39240, 31484, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39241, 31596, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39242, 31769, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39243, 31808, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39244, 31815, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39245, 31930, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39246, 31931, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39247, 31946, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39248, 31975, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39249, 31987, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39250, 32008, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39251, 32145, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39252, 32174, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39253, 32182, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39254, 32214, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39255, 32221, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39256, 33747, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39257, 33824, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39258, 33882, 'Cholecalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39259, 13865, 'Ciclesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39260, 13867, 'Ciclesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39261, 28040, 'Ciclesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39262, 28041, 'Ciclesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39263, 28042, 'Ciclesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39264, 13865, 'Ciclesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39265, 13867, 'Ciclesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39266, 28040, 'Ciclesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39267, 28041, 'Ciclesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39268, 28042, 'Ciclesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39269, 13865, 'Ciclesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39270, 13867, 'Ciclesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39271, 28040, 'Ciclesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39272, 28041, 'Ciclesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39273, 28042, 'Ciclesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39274, 13865, 'Ciclesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39275, 13867, 'Ciclesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39276, 28040, 'Ciclesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39277, 28041, 'Ciclesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39278, 28042, 'Ciclesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39279, 0, 'Cidofovir', 'Dehydration', 'Cidofovir is associated with dose-dependent nephrotoxicity, which is minimized by adequate hydration.  One liter of normal saline should be infused over 1 to 2 hours prior to each dose of cidofovir in normal adults.  Therapy with cidofovir should be administered cautiously in patients who are dehydrated.  These patients may be candidates for an additional liter, given over 1 to 3 hours upon the initiation or completion of cidofovir infusion.', '3', '"Product Information. Vistide (cidofovir)." Gilead Sciences  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39280, 0, 'Cidofovir', 'Neutropenia', 'Cidofovir may cause neutropenia (20% in clinical trials).  Therapy with cidofovir should be administered cautiously in patients with preexisting neutropenia or those receiving concomitant drugs with myelosuppressive effects.  With some drugs (e.g., zidovudine or AZT), a temporary interruption of therapy or a reduction in dosage may be necessary on days of cidofovir administration.  Close monitoring of neutrophil count is recommended during therapy with cidofovir.  Some patients may be candidates for granulocyte colony stimulating factor.', '3', '"Product Information. Vistide (cidofovir)." Gilead Sciences  (2001):|Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, et al. "(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue." J Infect Dis 171 (1995):  788-96', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39281, 0, 'Cidofovir', 'Kidney Diseases', 'The initiation of cidofovir therapy is contraindicated in patients with renal impairment defined by a serum creatinine > 1.5 mg/dL, a calculated creatinine clearance <= 55 mL/min, or a urine protein >= 100 mg/dL (i.e., 2+ proteinuria).  Cidofovir is associated with dose-dependent nephrotoxicity, which may result in acute renal failure and the need for dialysis in some cases, as well as Fanconi''s syndrome.  Patients with normal renal function or mild dysfunction should be monitored closely for declining renal function during cidofovir therapy, and the dosing adjusted or discontinued accordingly.  Renal function should be assessed within 48 hours preceding each dose.', '3', '"Product Information. Vistide (cidofovir)." Gilead Sciences  (2001):|Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, et al. "(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue." J Infect Dis 171 (1995):  788-96|Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, Falloon J, Davey RT Jr, Kovacs JA, Walker RE, et al. "Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria." Antimicrob Agents Chemother 39 (1995):  882-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39282, 2707, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39283, 2710, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39284, 6465, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39285, 16329, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39286, 16330, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39287, 16331, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39288, 16332, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39289, 16451, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39290, 16453, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39291, 16455, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39292, 16581, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39293, 16583, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39294, 20796, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39295, 23018, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39296, 25010, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39297, 25011, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39298, 26692, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39299, 26693, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39300, 26816, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39301, 26817, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39302, 27487, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39303, 27488, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39304, 27489, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39305, 27952, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39306, 31976, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39307, 2707, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39308, 2710, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39309, 6465, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39310, 16329, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39311, 16330, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39312, 16331, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39313, 16332, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39314, 16451, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39315, 16453, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39316, 16455, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39317, 16581, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39318, 16583, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39319, 20796, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39320, 23018, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39321, 25010, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39322, 25011, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39323, 26692, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39324, 26693, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39325, 26816, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39326, 26817, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39327, 27487, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39328, 27488, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39329, 27489, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39330, 27952, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39331, 31976, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39332, 2707, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39333, 2710, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39334, 6465, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39335, 16329, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39336, 16330, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39337, 16331, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39338, 16332, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39339, 16451, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39340, 16453, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39341, 16455, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39342, 16581, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39343, 16583, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39344, 20796, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39345, 23018, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39346, 25010, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39347, 25011, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39348, 26692, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39349, 26693, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39350, 26816, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39351, 26817, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39352, 27487, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39353, 27488, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39354, 27489, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39355, 27952, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39356, 31976, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39357, 2707, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39358, 2710, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39359, 6465, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39360, 16329, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39361, 16330, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39362, 16331, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39363, 16332, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39364, 16451, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39365, 16453, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39366, 16455, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39367, 16581, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39368, 16583, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39369, 20796, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39370, 23018, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39371, 25010, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39372, 25011, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39373, 26692, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39374, 26693, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39375, 26816, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39376, 26817, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39377, 27487, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39378, 27488, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39379, 27489, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39380, 27952, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39381, 31976, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '"Product Information. Pletal (cilostazol)." Otsuka American Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39382, 0, 'Chorionic Gonadotropin (Human)', 'Prostatic Neoplasms', 'The use of chorionic gonadotropin is contraindicated for use in patients with prostatic or other androgen- dependent neoplasm.  HCG activity is identical to that of luteinizing hormone (LH) and, to a small degree, that of follicle-stimulating hormone (FSH), resulting in production of androgens by the testis.', '3', '"Product Information. Pregnyl (chorionic gonadotropin (HCG))." Organon', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39383, 0, 'Chorionic Gonadotropin (Human)', 'Edema', 'Chorionic gonadotropin (HCG) induction of androgen secretion can result in fluid retention.  Therapy with chorionic gonadotropin (HCG) should be administered cautiously in patients adversely affected by sodium and water retention such as patients with cardiac or renal disease, epilepsy, migraine or asthma.', '2', '"Product Information. Pregnyl (chorionic gonadotropin (HCG))." Organon', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39384, 13865, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39385, 13867, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39386, 28040, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39387, 28041, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39388, 28042, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39389, 13865, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39390, 13867, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39391, 28040, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39392, 28041, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39393, 28042, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39394, 13865, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39395, 13867, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39396, 28040, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39397, 28041, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39398, 28042, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39399, 13865, 'Ciclesonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39400, 13867, 'Ciclesonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39401, 28040, 'Ciclesonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39402, 28041, 'Ciclesonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39403, 28042, 'Ciclesonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39404, 25331, 'Aldesleukin', 'Autoimmune Diseases', 'Aldesleukin may exacerbate existing or activate quiescent autoimmune disease.  Therapy with aldesleukin should be administered cautiously in patients with autoimmune diseases.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39405, 25331, 'Aldesleukin', 'Cardiovascular Diseases', 'The use of aldesleukin is contraindicated in patients with abnormal cardiac function as indicated by a thallium stress test.  Therapy with aldesleukin should be administered with extreme caution in patients with a normal thallium stress test who have a history of cardiac disease.  Close clinical monitoring of cardiac function is required.  When adverse events occur that require dosage modification, dosages should be withheld rather than reduced .  Subsequent treatment with aldesleukin is contraindicated in patients with sustained ventricular tachycardia, rhythm disturbances uncontrolled or unresponsive to management,  recurrent chest pain with ECG changes consistent with angina or myocardial infarction, or pericardial tamponade.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39406, 25331, 'Aldesleukin', 'Edema', 'Aldesleukin can cause Capillary Leak Syndrome resulting in ascites or pulmonary edema.  Administration of IV fluids may be necessary to maintain organ perfusion and blood pressure.  Aldesleukin should be administered cautiously in patients with fixed fluid requirements and/or those adversely affected by fluid overload.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39407, 25331, 'Aldesleukin', 'Liver Diseases', 'Hepatotoxicity such as elevated bilirubin, transaminase and alkaline phosphatase levels have been reported in over 55% of patients administered aldesleukin.  Hepatotoxicity is generally reversible, however, hepatic failure resulting in death has been reported.  Therapy with aldesleukin should be administered cautiously in patients with compromised hepatic function.   When adverse events occur that require dosage modification, dosages should be withheld rather than reduced.  Clinical monitoring of hepatic function is recommended.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39408, 25331, 'Aldesleukin', 'Hypotension', 'Hypotension, primarily associated with capillary leak syndrome, has been reported in 85% of patients administered aldesleukin.  Seventy-one percent of patients with hypotension required pressor management.  Therapy with aldesleukin should be administered cautiously in patients predisposed to hypotension.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39409, 25331, 'Aldesleukin', 'Bone Marrow Failure Disorders', 'Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia.  Leukopenia has been reported.  Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve.  Clinical monitoring of hematopoietic function is recommended.  Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39410, 25331, 'Aldesleukin', 'Neutropenia', 'The use of aldesleukin may be contraindicated in patients with infections, particularly bacterial diseases.  Aldesleukin can interfere with neutrophil chemotaxis and increase the risk of disseminated infections, including bacterial endocarditis and sepsis.  Therefore, preexisting bacterial infections should be adequately treated prior to initiation of aldesleukin therapy.  Close clinical monitoring of hematopoietic function is recommended during therapy.  Since there is increasing evidence that neutrophils may also play important roles in viral and other infections, it may be reasonable in some cases to defer aldesleukin treatment in patients with active nonbacterial infections.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39411, 25331, 'Aldesleukin', 'Respiratory Insufficiency', 'The use of aldesleukin should be restricted to patients with adequate ventilatory function (baseline FEV1 > 2 L or >= 75% of the predicted value based on height and age).  Extreme caution should be used in treating patients with normal test results but have a history of pulmonary disease.  Pulmonary congestion and dyspnea have been reported in over 50% of patients receiving the recommended dosage of aldesleukin.  Respiratory adverse effects are often associated with the capillary leak syndrome induced by aldesleukin and may also include pulmonary edema, respiratory failure requiring intubation, tachypnea, pleural effusion, wheezing, apnea, pneumothorax, hemoptysis, respiratory arrest, and pulmonary emboli.  During therapy, pulmonary function should be monitored regularly by clinical examination, assessment of vital signs and pulse oximetry, and arterial blood gas determinations as needed.  When toxicities occur that require a dosage modification, doses should be withheld rather than reduced.  Subsequent treatment with aldesleukin is contraindicated in patients who develop respiratory failure requiring intubation for longer than 72 hours.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39412, 25331, 'Aldesleukin', 'Kidney Diseases', 'Renal toxicity such as oliguria/anuria and elevated BUN and serum creatinine has been reported in > 60% of patients during aldesleukin therapy.  Renal toxicity is generally reversible, however, patients with renal impairment are at increased risk for more severe and prolonged renal dysfunction.  Therapy with aldesleukin should be administered cautiously in patients with compromised renal function.  Clinical monitoring of renal function is recommended.  When adverse events occur that require dosage modification, dosages should be withheld rather than reduced.  Subsequent treatment with aldesleukin is contraindicated in patients experiencing renal dysfunction that requires greater than seventy-two hours of dialysis.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39413, 25331, 'Aldesleukin', 'Seizures', 'Aldesleukin can induce seizures.  Therapy with aldesleukin should be administered with extreme caution in patients with or predisposition to seizure disorders.   When adverse events occur that require dosage modification, dosages should be withheld rather than reduced .  Subsequent treatment with aldesleukin is contraindicated in patients with repetitive or difficult to control seizures.', '3', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39414, 25331, 'Aldesleukin', 'Mental Disorders', 'Mental status changes such as lethargy, somnolence, depression, confusion or agitation were reported in over 70% of patients administered aldesleukin.  Therapy with aldesleukin should be administered cautiously to patients with or predisposition to altered mental status.   When adverse events occur that require dosage modification, dosages should be withheld rather than reduced.  Clinical monitoring of mental status is recommended.', '2', '"Product Information. Proleukin (aldesleukin)." Chiron Therapeutics  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39415, 7108, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39416, 7109, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39417, 7110, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39418, 8736, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39419, 23449, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39420, 23451, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39421, 25339, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39422, 25340, 'Chlorpromazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '"Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):|"Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):|"Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company  (2001):|"Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2007):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2009):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2009):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2010):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):|"Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.  (2015):|"Product Information. Nuplazid (pimavanserin)." Accelis Pharma  (2016):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39423, 7108, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39424, 7109, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39425, 7110, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39426, 8736, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39427, 23449, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39428, 23451, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39429, 25339, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39430, 25340, 'Chlorpromazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39431, 7108, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39432, 7109, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39433, 7110, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39434, 8736, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39435, 23449, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39436, 23451, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39437, 25339, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39438, 25340, 'Chlorpromazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'Varia I, Krishnan R, Davidson J "Deep-vein thrombosis with antipsychotic drugs." Psychosomatics 24 (1983):  1097-8|Schreiber G, Belmaker R "In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol." Biol Psychiatry 22 (1987):  1417-21|Witz L, Shapiro M, Shenkman L "Chlorpromazine induced fluid retention masquerading as idiopathic oedema." Br Med J 294 (1987):  807-8|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985):  274|Stevenson R, Blanshard C, Patterson D "Ventricular fibrillation due to lithium withdrawal: an interaction with chlorpromazine?" Postgrad Med J 65 (1989):  936-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969):  135-8|Margolis J "Massive edema induced by thioridazine (Mellaril): an unusual complication." J Am Geriatr Soc 20 (1972):  593-4|Kumar BB "Letter: Acute hypotension from thioridazine." JAMA 234 (1975):  1321|Jones J, Sklar D, Dougherty J, White W "Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache." JAMA 261 (1989):  1174-6|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39439, 7108, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39440, 7109, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39441, 7110, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39442, 8736, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39443, 23449, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39444, 23451, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39445, 25339, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39446, 25340, 'Chlorpromazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39447, 7108, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39448, 7109, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39449, 7110, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39450, 8736, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39451, 23449, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39452, 23451, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39453, 25339, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39454, 25340, 'Chlorpromazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Dilsaver SC "Effects of neuroleptics on body temperature" J Clin Psychiatry 49 (1988):  78-9|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Keshavan MS, Kambhampati RK "Prolonged fever without extrapyramidal symptoms during neuroleptic  treatment" J Clin Psychopharmacol 9 (1989):  230-1|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39455, 7108, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39456, 7109, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39457, 7110, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39458, 8736, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39459, 23449, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39460, 23451, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39461, 25339, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39462, 25340, 'Chlorpromazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39463, 7108, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39464, 7109, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39465, 7110, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39466, 8736, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39467, 23449, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39468, 23451, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39469, 25339, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39470, 25340, 'Chlorpromazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'Ash PR, Bouma D "Exaggerated hyperprolactinemia in response to thiothixene ." Arch Neurol 38 (1981):  534-5|Ristic PI, Ory SJ, Lurain JR "Endometrial adenocarcinoma associated with drug-induced hyperprolactinemia." Obstet Gynecol 67 (1986):  s86-8|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Kane JM "Antipsychotic drug side effects: their relationship to dose." J Clin Psychiatry 46 (1985):  16-21|Gift T, Plum K, Price M "Depot fluphenazine and plasma prolactin." Prog Neuropsychopharmacol Biol Psychiatry 9 (1985):  407-12|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39471, 7108, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39472, 7109, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39473, 7110, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39474, 8736, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39475, 23449, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39476, 23451, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39477, 25339, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39478, 25340, 'Chlorpromazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'Wood G, Waters A "Prolonged dystonic reaction to chlorpromazine in myxoedema coma." Postgrad Med J 56 (1980):  192-3|Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Idzorek S "Antiparkinsonian agents and fluphenazine decanoate." Am J Psychiatry 133 (1976):  80-2|Bailie GR, Nelson MV, Krenzelok EP, Lesar T "Unusual treatment response of a severe dystonia to diphenhydramine." Ann Emerg Med 16 (1987):  705-8|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E "Acute dystonia during fixed-dose neuroleptic treatment." J Clin Psychopharmacol 10 (1990):  389-96|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Reecer MV, Clinchot DM, Tipton DB "Drug-induced dystonia in a patient with C4 quadriplegia. Case report." Am J Phys Med Rehabil 72 (1993):  97-8|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Lamont S "Acute reactions to phenothiazine derivatives." Br J Anaesth 44 (1972):  539-40|Schumock GT, Martinez E "Acute oculogyric crisis after administration of prochlorperazine." South Med J 84 (1991):  407-8|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|Harries JR "Oculogyric crises due to phenothiazines." Br Med J 3 (1967):  241|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39479, 7108, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39480, 7109, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39481, 7110, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39482, 8736, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39483, 23449, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39484, 23451, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39485, 25339, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39486, 25340, 'Chlorpromazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'Stein P, Inwood M "Hemolytic anemia associated with chlorpromazine therapy." Can J Psychiatry 25 (1980):  659-61|Holt R "Neuroleptic drug-induced changes in platelet levels." J Clin Psychopharmacol 4 (1984):  130-2|Yassa R "Agranulocytosis in the course of phenothiazine therapy." J Clin Psychiatry 46 (1985):  341-3|Zengotita H, Holt R "Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect." J Clin Psychiatry 47 (1986):  35-7|Aram H "Henoch-Schonlein purpura induced by chlorpromazine." J Am Acad Dermatol 17 (1987):  139-40|Young A, Kehoe R "Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment." Br J Psychiatry 154 (1989):  710-12|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Rosenthal DS, Stein GF, Santos JC "Thioridazine agranulocytosis." JAMA 200 (1967):  81-2|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39487, 7108, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39488, 7109, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39489, 7110, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39490, 8736, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39491, 23449, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39492, 23451, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39493, 25339, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39494, 25340, 'Chlorpromazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Maxwell JD, Carrella M, Parkes JD, et al. "Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis." Clin Sci 43 (1972):  143-51|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|Simpson GM, Yadalam KG, Levinson DF, et al. "Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration." J Clin psychopharmacol 10 (1990):  417-21|Hu OY, Tang H-S, Sheeng T-Y, et al. "Pharmacokinetics of promazine I: disposition in patients with acute viral hepatitis B." Biopharm Drug Dispos 11 (1990):  557-68|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Barancik M, Brandborg LL, Albion MJ "Thioridazine-induced cholestasis." JAMA 200 (1967):  69-70|Reinhart MJ, Benson RM, Kwass SK, Storey WF "Suggestive evidence of hepatotoxicity concomitant with thioridazine hydrochloride use." JAMA 197 (1966):  767-9|Snyder S "Fluphenazine jaundice. Report of a case." Am J Gastroenterol 73 (1980):  336-40|Holt RJ "Fluphenazine decanoate-induced cholestatic jaundice and  thrombocytopenia." Pharmacotherapy 4 (1984):  227-9|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Podevin P, Biour M "Drug-induced ''''allergic hepatitis''''." Clin Rev Allergy Immunol 13 (1995):  223-44|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39495, 7108, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39496, 7109, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39497, 7110, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39498, 8736, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39499, 23449, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39500, 23451, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39501, 25339, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39502, 25340, 'Chlorpromazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'Morris H, McCormick W, Reinarz J "Neuroleptic malignant syndrome." Arch Neurol 37 (1980):  462-3|Price W, Giannini A "A paradoxical response to chlorpromazine: a possible variant of the neuroleptic malignant syndrome." J Clin Pharmacol 23 (1983):  567-9|Tenenbein M "The neuroleptic malignant syndrome: occurrence in a 15-year-old boy and recovery with bromocriptine therapy." Pediatr Neurosci 12 (1985):  161-4|Caroff SN "The neuroleptic malignant syndrome." J Clin Psychiatry 41 (1980):  79-83|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Zubenko G, Pope HG, Jr "Management of a case of neuroleptic malignant syndrome with  bromocriptine." Am J Psychiatry 140 (1983):  1619-20|Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S "Neuroleptic malignant syndrome: successful treatment with dantrolene  and bromocriptine." Ann Neurol 14 (1983):  89-90|Grunhaus L, Sancovici S, Rimon R "Neuroleptic malignant syndrome due to depot fluphenazine." J Clin Psychiatry 40 (1979):  99-100|Dhib-Jalbut S, Hesselbrock R, Brott T, Silbergeld D "Treatment of the neuroleptic malignant syndrome with bromocriptine" JAMA 250 (1983):  484-5|Caroff S, Rosenberg H, Gerber JC "Neuroleptic malignant syndrome and malignant hyperthermia" Lancet 1 (1983):  244|Rampertaap MP "Neuroleptic malignant syndrome." South Med J 79 (1986):  331-6|West D "Dangers of fluphenazine." Br J Psychiatry 117 (1970):  718-9|Manser TJ, Warner JF "Neuroleptic malignant syndrome associated with prochlorperazine." South Med J 83 (1990):  73-4|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39503, 7108, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39504, 7109, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39505, 7110, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39506, 8736, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39507, 23449, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39508, 23451, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39509, 25339, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39510, 25340, 'Chlorpromazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Rajput A, Rozdilsky B, Hornykiewicz O, et al. "Reversible drug-induced parkinsonism." Arch Neurol 39 (1982):  6446|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Lamb P, Mindham RH, Ezzat MA "Letter: Parkinsonism induced by fluphenazine decanoate." Lancet 1 (1976):  484|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Edelstein H, Knight RT "Severe parkinsonism in two AIDS patients taking prochlorperazine." Lancet 2 (1987):  341-2|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39511, 7108, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39512, 7109, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39513, 7110, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39514, 8736, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39515, 23449, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39516, 23451, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39517, 25339, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39518, 25340, 'Chlorpromazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Taylor G, Houston JB, Shaffer J, Mawer G "Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man." Br J Clin Pharmacol 15 (1983):  287-93|Fabre J, Freudenreich J, de  Duckert A, Pitton JS, Rudhardt M, Virieux C "Influence of renal insufficiency on the excretion of chloroquine, phenobarbital, phenothiazines and methacycline." Helv Med Acta 33 (1967):  307-16|McAllister CJ, Scowden EB, Stone WJ "Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure." Clin Nephrol 10 (1978):  191-5|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39519, 7108, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39520, 7109, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39521, 7110, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39522, 8736, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39523, 23449, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39524, 23451, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39525, 25339, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39526, 25340, 'Chlorpromazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'Seeff L "Drug-induced chronic liver disease, with emphasis on chronic active hepatitis." Semin Liver Dis 1 (1981):  104-15|Dossing M, Andreasen B "Drug-induced liver disease in Denmark." Scand J Gastroenterol 17 (1982):  205-11|Dorson P, Crismon M "Chlorpromazine accumulation and sudden death in a patient with renal insufficiency." Drug Intell Clin Pharm 22 (1988):  776-8|Bach N, Thung S, Schaffner F, Tobias H "Exaggerated cholestasis and hepatic fibrosis following simultaneous administration of chlorpromazine and sodium valproate." Dig Dis Sci 34 (1989):  1303-7|Ben-Yehuda A, Bloom A, Lijhovetzky G, et al. "Chlorpromazine-induced liver and bone marrow granulomas associated with agranulocytosis." Isr J Med Sci 26 (1990):  449-51|Dahl SG, Strandjord RE "Pharmacokinetics of chlorpromazine after single and chronic dosage." Clin Pharmacol Ther 21 (1977):  437-48|Whitfield LR, Kaul PN, Clark ML "Chlorpromazine metabolism IX: pharmacokinetics of chlorpromazine following oral administration in man." J Pharmacokinet Biopharm 6 (1978):  187-96|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Derby LE, Gutthann SP, Jick H, Dean AD "Liver disorders in patients receiving chlorpromazine or isoniazid." Pharmacotherapy 13 (1993):  353-8|Chetty M, Moodley SV, Miller R "Important metabolites to measure in pharmacodynamic studies of chlorpromazine." Ther Drug Monit 16 (1994):  30-6|Lok AS, Ng IO "Prochlorperazine-induced chronic cholestasis." J Hepatol 6 (1988):  369-73|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M "Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis." Hepatology 20 (1994):  1437-41|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39527, 7108, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39528, 7109, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39529, 7110, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39530, 8736, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39531, 23449, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39532, 23451, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39533, 25339, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39534, 25340, 'Chlorpromazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'Markowitz J, Brown R "Seizures with neuroleptics and antidepressants." Gen Hosp Psychiatry 9 (1987):  135-41|Waterhouse RG "Epileptiform convulsions in children following premedication with Pamergan SP100." Br J Anaesth 39 (1967):  268-70|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39535, 7108, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39536, 7109, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39537, 7110, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39538, 8736, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39539, 23449, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39540, 23451, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39541, 25339, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39542, 25340, 'Chlorpromazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'Yassa R, Dimitry R "Single phenothiazines and tardive dyskinesia." J Clin Psychiatry 44 (1983):  233-4|Mariani P "Adverse reactions to chlorpromazine in the treatment of migraine." Ann Emerg Med 17 (1988):  380-1|Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987):  913-5|Schwinghammer TL, Kroboth FJ, Juhl RP "Extrapyramidal reaction secondary to oral promethazine." Clin Pharm 3 (1984):  83-5|Marcotte DB "Neuroleptics and neurologic reactions." South Med J 66 (1973):  321-4|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Sparine (promazine)." Wyeth-Ayerst Laboratories  (2001):|Csernansky JG, Grabowski K, Cervantes J, Kaplan J, Yesavage JA "Fluphenazine decanoate and tardive dyskinesia: a possible  association." Am J Psychiatry 138 (1981):  1362-5|Perenyi A, Arato M "Fluphenazine and tardive dyskinesia" Arch Gen Psychiatry 41 (1984):  727|Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S "Tardive dyskinesia in psychiatric outpatients: a study of prevalence  and association with demographic, clinical, and drug history  variables." Arch Gen Psychiatry 39 (1982):  466-9|Kolakowska T, Williams AO, Ardern M "Tardive dyskinesia and current dose of neuroleptic drugs" Arch Gen Psychiatry 42 (1985):  925|Glazer WM, Moore DC "The diagnosis of rapid abnormal involuntary movements associated with  fluphenazine decanoate." J Nerv Ment Dis 168 (1980):  439-41|McClelland HA, Metcalfe AV, Kerr TA, Dutta D, Watson P "Facial dyskinesia: a 16-year follow-up study" Br J Psychiatry 158 (1991):  691-6|Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC "Long-term depot maintenance of chronic schizophrenic out-patients:  the seven year follow-up of the Medical Research Council  fluphenazine/placebo trial. II. The incidence of compliance problems,side-effects, neurotic symptoms and depression" Br J Psychiatry 146 (1985):  469-74|Yassa R, Iskandar H, Ally J "The prevalence of tardive dyskinesia in fluphenazine-treated  patients." J Clin Psychopharmacol 8 (1988):  17S-20S|Oyewumi LK, Lapierre YD, Gray R, Batth S, Gelfand R "Abnormal involuntary movements in patients on long-acting  neuroleptics." Prog Neuropsychopharmacol Biol Psychiatry 7 (1983):  719-23|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Baker FM, Cook P "Compazine complications: a review." J Natl Med Assoc 73 (1981):  409-12|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|"Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb  (2001):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Serentil (mesoridazine)." Boehringer-Ingelheim  (2001):|"Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc  (2001):|"Product Information. Trilafon (perphenazine)." Schering Corporation  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|"Product Information. Stelazine (trifluoperazine)." SmithKline Beecham  (2001):|"Product Information. Vesprin (triflupromazine)." Bristol-Myers Squibb  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39543, 16649, 'Chlorthalidone', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39544, 16649, 'Chlorthalidone', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', 'Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Leigh H "Letter: Factitious hypokalemia." Ann Intern Med 80 (1974):  111-2|Moore TD, Bechtel TP "Hyponatremia secondary to tolbutamide and chlorothiazide." Am J Hosp Pharm 36 (1979):  1107-10|Falch DK, Schreiner AM "Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone." Acta Med Scand 209 (1981):  111-4|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985):  1045-59|Remenchik AP, Johnston LC "Potassium depletion produced by administration of chlorthalidone to nonedematous patients with arterial hypertensin." Am J Med Sci 252 (1966):  171-6|Katz FH, Eckert RC, Gebott MD "Hypokalemia caused by surreptitious self-administration of diuretics." Ann Intern Med 76 (1972):  85-90|Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971):  853-63|Stewart DE, Ikram H, Espiner EA, Nicholls MG "Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease." Br Heart J 54 (1985):  290-7|Kuller LH, Hulley SB, Cohen JD, Neaton J "Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis." Circulation 73 (1986):  114-23|Landmann-Suter R, Struyvenberg A "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction." Eur J Clin Invest 8 (1978):  155-64|Navarro RP, O''Brien DK, Nuffort P, Spencer DL "Diuretic induced hypokalemia in the elderly." J Fam Pract 14 (1982):  685-9|Oh SJ, Douglas JE, Brown RA "Hypokalemic vacuolar myopathy associated with chlorthalidone treatment." JAMA 216 (1971):  1858-9|Mozes B, Pines A, Werner D, Olchovsky D, Lieberman P, Frankl O "Thiazide-induced hyponatremia: an unusual neurologic course." South Med J 79 (1986):  629-31|Jensen OB, Mosdal C, Reske-Nielsen E "Hypokalemic myopathy during treatment with diuretics." Acta Neurol Scand 55 (1977):  465-82|Cembrowski GS, Huntington RW, 3d "Probable fatal cardiac dysrhythmia secondary to diuretic-induced hypokalemia." Am J Forensic Med Pathol 2 (1981):  243-8|Sumiye L, Vivian AS, Frisof KB, Podany EC "Potassium loss associated with hydrochlorothiazide versus chlorthalidone." Clin Ther 4 (1981):  308-20|Berg KJ, Gisholt K, Wideroe TE "Potassium deficiency in hypertensives treated with diuretics. Analysis of three alternative treatments by an oral test for potassium deficiency." Eur J Clin Pharmacol 7 (1974):  401-5|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987):  143-8|Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981):  67-73|Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985):  595-9|Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983):  1017-22|Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988):  329-31|Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  175-6|Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978):  48|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986):  634|Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986):  341|Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980):  1975-6|Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990):  739-42|Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989):  966-9,|Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986):  1456-7|Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988):  380-5|Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991):  165-8|Kaur J, Wahi PL "Polythiazide as a diuretic. A clinical trial." J Indian Med Assoc 48 (1967):  13-7|Mroczek WJ "Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects." Pharmacotherapy 3 (1983):  61-7|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Stern A "Metolazone, a diuretic agent." Am Heart J 91 (1976):  262-3|Black W, Shiner P, Roman J "Severe electrolyte disturbances associated with metolazone and furosemide." South Med J 71 (1978):  381|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Ghose RR "Letter: Hyponatraemia and diuretics." Lancet 1 (1975):  578-9|Brors O, Enger E, Jacobsen S, Aakvaag A, Foss OP "Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone." Acta Pharmacol Toxicol (Copenh) 49 (1981):  399-406|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Husby S, Marthedal NJ "Hyponatraemia due to a thiazide diuretic. A case report." Acta Med Scand 210 (1981):  523-4|Berglund G, Andersson O, Larsson O, Wilhelmsen L "Antihypertensive effect and side-effects of bendroflumethiazide and propranolol." Acta Med Scand 199 (1976):  499-506|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Condon JR, Nassim R "Hypophosphataemia and hypokalaemia." Br Med J 1 (1970):  110|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Lee MR, Morgan DB "Familial hyperkalaemia responsive to benzothiadiazine diuretic." Lancet 1 (1980):  879|Hesp R, Wilkinson PR "Potassium supplementation of thiazide therapy." Lancet 2 (1976):  1144|Struthers AD, Whitesmith R, Reid JL "Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia." Lancet 1 (1983):  1358-61|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Starr JM, Whalley LJ "Hypertensive Old People in Edinburgh (HOPE) Study: electrocardiographic changes after captopril or bendrofluazide treatment." Age Ageing 22 (1993):  343-8|Toner JM, Ramsay LE "Thiazide-induced hypokalaemia; prevalence higher in women." Br J Clin Pharmacol 18 (1984):  449-52|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|Medical Research Council Working Party on Mild to Moderate Hypertension. "Ventricular extrasystoles during thiazide treatment: substudy of MRC mild hypertension trial." Br Med J (Clin Res Ed) 287 (1983):  1249-53|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Chan TY "Indapamide-induced severe hyponatremia and hypokalemia." Ann Pharmacother 29 (1995):  1124-8|Simunic M, Rumboldt Z, Ljutic D, Sardelic S "Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients." J Clin Pharmacol 35 (1995):  1150-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39545, 16649, 'Chlorthalidone', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', 'Aneckstein AG, Weingold AB "Chlorothiazide-induced hepatic coma in pregnancy." Am J Obstet Gynecol 95 (1966):  136-7|Sherlock S, Senewiratne B, Scott A, Walker JG "Complications of diuretic therapy in hepatic cirrhosis." Lancet 1 (1966):  1049-52|Sherlock S, Walker JG, Senewiratne B, Scott A "The complications of diuretic therapy in patients with cirrhosis." Ann N Y Acad Sci 139 (1966):  497-505|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39546, 16649, 'Chlorthalidone', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', 'Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985):  49-51|Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989):  100-2|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993):  1001-2|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995):  1001|Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995):  729-33', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39547, 16649, 'Chlorthalidone', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', 'Fleuren HLJ, Verwey-van Wissen C, van Rossum JM "Dose-dependent urinary excretion of chlorthalidone." Clin Pharmacol Ther 25 (1979):  806-12|Beermann B, Groschinsky-Grind M, Rosen A "Absorption, metabolism, and excretion of hydrochlorothiazide." Clin Pharmacol Ther 19 (1975):  531-7|Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|Gehr TW, Sica DA, Brater DC, et al. "Metolazone pharmacokinetics and pharmacodynamics in renal transplantation." Int J Clin Pharmacol Ther Toxicol 29 (1991):  116-23|Jones B, Nanra RS "Double-blind trial of antihypertensive effect of chlorothiazide in severe renal failure." Lancet 2 (1979):  1258-60|Carney SL, Morgan TO "Diuretic-induced hypokalemia and altered renal function." Int J Clin Pharmacol Ther Toxicol 24 (1986):  665-7|Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980):  939-43|Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983):  36-41|Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973):  992|Riess W, Dubach UC, Burckhardt D, Theobald W, Vuillard P, Zimmerli M "Pharmacokinetic studies with chlorthalidone (Hygroton) in man." Eur J Clin Pharmacol 12 (1977):  375-82|Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC "Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure." Clin Pharmacol Ther 16 (1974):  322-9|Bennett WM, Porter GA "Efficacy and safety of metolazone in renal failure and the nephrotic syndrome." J Clin Pharmacol 13 (1973):  357-64|Craswell PW, Ezzat E, Kopstein J, Varghese Z, Moorhead JF "Use of metolazone, a new diuretic, in patients with renal disease." Nephron 12 (1974):  63-73|Acchiardo SR, Skoutakis VA "Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment." Am Heart J 106 (1983):  237-44|Brennan L, Wu MJ, Laquer UJ "A multicenter study of indapamide in hypertensive patients with impaired renal function." Clin Ther 5 (1982):  121-8|Klunk LJ, Ringel S, Neiss ES "The disposition of 14C-indapamide in man." J Clin Pharmacol 23 (1983):  377-84|Newstead CG, Moore RH, Barnes AJ "Interstitial nephritis associated with indapamide." BMJ 300 (1990):  1344|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.  (1990):|Seyffart, G "Drug Dosage in Renal Insufficiency." Dordrecht, The Netherlands:  Kluwer Academic Publishers 1 (1991):  227-8|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Hobbs DC, Twomey TM "Kinetics of polythiazide." Clin Pharmacol Ther 23 (1978):  241-6|Lant AF, Baba WI, Wilson GM "Localization of the site of action of oral diuretics in the human kidney." Clin Sci 33 (1967):  11-27|Brors O, Jacobsen S "Distribution of elimination of hydroflumethiazide in man." Eur J Clin Pharmacol 16 (1979):  125-31|Brors O, Haffner JF, Jacobsen S "Excretion of hydroflumethiazide in bile and urine of man." Eur J Clin Pharmacol 15 (1979):  287-9|Yakatan GJ, Smith RB, Frome EL, Doluisio JT "Pharmacokinetics of orally administered hydroflumethiazide in man." J Clin Pharmacol 17 (1977):  37-47|el-Meheiry MM, Nabih AE, Soliman MD "A clinical study of a new diuretic, Trichlormethiazide." J Trop Med Hyg 69 (1966):  209-14|Sketris IS, Skoutakis VA, Acchiardo SR, Meyer MC "The pharmacokinetics of trichlormethiazide in hypertensive patients with normal and compromised renal function." Eur J Clin Pharmacol 20 (1981):  453-7|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Larsson GB, Langer L, Nassberger L "Thiazide-induced kidney damage with circulating antibodies against myeloperoxidase and cardiolipin." J Intern Med 233 (1993):  493-4|Beermann B, Groschinsky-Grind M, Lindstrom B "Pharmacokinetics of bendroflumethiazide." Clin Pharmacol Ther 22 (1977):  385-8|Beermann B, Groschinsky-Grind M, Lindstrom B, Wikland B "Pharmacokinetics of bendroflumenthiazide in hypertensive patients." Eur J Clin Pharmacol 13 (1978):  119-24|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Read SJ, Trenerry HM, Whiting GF "Hyponatraemia and raised creatine kinase level associated with indapamide." Med J Aust 161 (1994):  607-8|Madkour H, Gadallah M, Plante GE, Massry SG "Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension." Am J Nephrol 15 (1995):  251-5|Brater DC "Drug therapy: Diuretic therapy." N Engl J Med 339 (1998):  387-95', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39548, 16649, 'Chlorthalidone', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', '"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39549, 16649, 'Chlorthalidone', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969):  556-60|Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978):  1887-8|Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969):  1372-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972):  1592-3|Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970):  13-6|Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972):  1741-2|Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967):  209-10|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982):  1293-5|Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969):  19-28|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993):  99-103,|Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993):  860|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985):  25-6|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986):  631-6|Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981):  154-63|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Berglund G, Andersson O, Widgren B "Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide." Acta Med Scand 220 (1986):  419-24|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Nielsen S, Schmitz A, Knudsen RE, Dollerup J, Mogensen CE "Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension." Q J Med 87 (1994):  747-54|Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995):  853-9|Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996):  861-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39550, 16649, 'Chlorthalidone', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', 'Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Ames RP, Hill P "Increase in serum-lipids during treatment of hypertension with chlorthalidone." Lancet 1 (1976):  721-3|Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989):  868-73|Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983):  283-96|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC "The effects of terazosin and methyclothiazide on blood pressure and serum lipids." Am Heart J 117 (1989):  842-7|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Smith WM "Diuretics and cholesterol elevation." JAMA 242 (1979):  1612|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995):  133-41|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6|Ames RP "A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides." Am J Cardiol 77 (1996):  b12-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39551, 16649, 'Chlorthalidone', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', 'Anderson PE, Ellis GG, Austin SM "Case report: metolazone-associated hypercalcemia and acute pancreatitis." Am J Med Sci 302 (1991):  235-7|Lindy S, Tarssanen L "Serum calcium and phosphorus in patients treated with thiazides and furosemide." Acta Med Scand 194 (1973):  319-22|Gammon GD, Docherty JP "Thiazide-induced hypercalcemia in a manic-depressive patient." Am J Psychiatry 137 (1980):  1453-5|Parfitt AM "Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism." Ann Intern Med 77 (1972):  557-63|Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW "The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism." J Clin Invest 55 (1975):  1295-302|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Parfitt AM "Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism." N Engl J Med 281 (1969):  55-9|Palmer FJ "Letter: Chlorthalidone-induced hypercalcemia." JAMA 229 (1974):  267|Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979):  591-4|Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987):  161-2|Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990):  704-8|Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973):  1238-9|Paloyan E, Farland M, Pickleman JR "Hyperparathyroidism coexisting with hypertension and prolonged thiazide administration." JAMA 210 (1969):  1243-5|Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971):  828-30|Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981):  80-3|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Hilker RR "Reversible hypercalcemia associated with prolonged thiazide administration to control hypertension." J Occup Med 12 (1970):  444-5|Jorgensen FS, Brunner S "The long-term effect of bendroflumethiazide on renal calcium and magnesium excretion and stone formation in patients with recurring renal stones." Scand J Urol Nephrol 8 (1974):  128-31|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B "Calcium and magnesium metabolism during long-term treatment with thiazides." Scand J Urol Nephrol 15 (1981):  257-62|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39552, 16649, 'Chlorthalidone', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', 'Lapidus PW, Guidotti FP "Gout in orthopaedic practice: review of 232 cases." Clin Orthop 28 (1963):  97-110|Labeeuw M, Pozet N, Aissa AH, Zech PY, Sassard J, Laville M "Uric acid renal handling: spontaneous changes and influence of a thiazide alone or associated with triamterene." Int J Clin Pharmacol Ther Toxicol 26 (1988):  79-83|Beling S, Vukovich RA, Neiss ES, Zisblatt M, Webb E, Losi M "Long-term experience with indapamide." Am Heart J 106 (1983):  258-62|Slotkoff L "Clinical efficacy and safety of indapamide in the treatment of edema." Am Heart J 106 (1983):  233-7|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|Brors O, Jacobsen S, Foss OP, Aakvaag A "Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects." Acta Pharmacol Toxicol (Copenh) 48 (1981):  145-50|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|Gudbrandsson T, Hansson L "Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid." Acta Med Scand Suppl 625 (1979):  86-91|Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983):  79-83|Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980):  611-8|Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986):  151-5|Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Odlind B, Wikstrom B "Effects of bendroflumethiazide on urate metabolism during treatment of patients with renal stones." J Urol 127 (1982):  1207-10|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.|Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995):  223-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39553, 16649, 'Chlorthalidone', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', 'Bech K, Skovsted L, Siersbaek-Nielsen K, Hansen JM "Influence of thiazides on thyroid parameters in man." Acta Endocrinol (Copenh) 89 (1978):  673-8|"Product Information. HydroDIURIL (hydrochlorothiazide)." Merck & Co., Inc  (2002):|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Zaroxolyn (metolazone)." Rhone Poulenc Rorer  (2001):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Diuril (chlorothiazide)." Merck & Co., Inc  (2001):|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Metahydrin (trichlormethiazide)." Hoechst Marion Roussel  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Renese-R (reserpine-polythiazide)." Pfizer US Pharmaceuticals, New York, NY.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39554, 358, 'Cholic Acid', 'Liver Failure', 'Cholic acid should be used with caution in patients with liver impairment.  Some patients with liver disease at baseline experienced worsening serum transaminases, elevated bilirubin values, or worsening cholestasis on liver biopsy following treatment.  Liver function should be monitored and treatment with cholic acid should be discontinued in patients who develop worsening of liver function while on treatment.', '2', '"Product Information. Cholbam (cholic acid)." Manchester Pharmaceutical  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39555, 18277, 'Cholic Acid', 'Liver Failure', 'Cholic acid should be used with caution in patients with liver impairment.  Some patients with liver disease at baseline experienced worsening serum transaminases, elevated bilirubin values, or worsening cholestasis on liver biopsy following treatment.  Liver function should be monitored and treatment with cholic acid should be discontinued in patients who develop worsening of liver function while on treatment.', '2', '"Product Information. Cholbam (cholic acid)." Manchester Pharmaceutical  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39556, 23272, 'Cholic Acid', 'Liver Failure', 'Cholic acid should be used with caution in patients with liver impairment.  Some patients with liver disease at baseline experienced worsening serum transaminases, elevated bilirubin values, or worsening cholestasis on liver biopsy following treatment.  Liver function should be monitored and treatment with cholic acid should be discontinued in patients who develop worsening of liver function while on treatment.', '2', '"Product Information. Cholbam (cholic acid)." Manchester Pharmaceutical  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39557, 23273, 'Cholic Acid', 'Liver Failure', 'Cholic acid should be used with caution in patients with liver impairment.  Some patients with liver disease at baseline experienced worsening serum transaminases, elevated bilirubin values, or worsening cholestasis on liver biopsy following treatment.  Liver function should be monitored and treatment with cholic acid should be discontinued in patients who develop worsening of liver function while on treatment.', '2', '"Product Information. Cholbam (cholic acid)." Manchester Pharmaceutical  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39558, 0, 'Cinoxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39559, 0, 'Cinoxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39560, 0, 'Cinoxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39561, 0, 'Cinoxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39562, 2520, 'Cholestyramine', 'Cholestasis', 'The use of bile acid sequestrants is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine.  These agents adsorb and combine with bile acids in the intestine to form an insoluble complex that is excreted in the feces, resulting in partial removal of bile acids from the enterohepatic circulation.  Bile acid sequestrants are ineffective if bile does not reach the intestine.', '3', '"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39563, 25528, 'Cholestyramine', 'Cholestasis', 'The use of bile acid sequestrants is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine.  These agents adsorb and combine with bile acids in the intestine to form an insoluble complex that is excreted in the feces, resulting in partial removal of bile acids from the enterohepatic circulation.  Bile acid sequestrants are ineffective if bile does not reach the intestine.', '3', '"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39564, 25538, 'Cholestyramine', 'Cholestasis', 'The use of bile acid sequestrants is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine.  These agents adsorb and combine with bile acids in the intestine to form an insoluble complex that is excreted in the feces, resulting in partial removal of bile acids from the enterohepatic circulation.  Bile acid sequestrants are ineffective if bile does not reach the intestine.', '3', '"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39565, 2520, 'Cholestyramine', 'Constipation', 'The use of bile acid sequestrants may produce or worsen preexisting constipation.  Constipation associated with these agents may aggravate hemorrhoids.  Therapy with bile acid sequestrants should be administered cautiously in patients with preexisting constipation, hemorrhoids, or symptomatic coronary artery disease.  The dosage should be increased very gradually according to manufacturer guidelines to minimize the risk of fecal impaction, and patients should be encouraged to increase fluid and fiber intake.  Occasional use of a stool softener may also be indicated.  If constipation worsens or develops during therapy, or the desired therapeutic response is not achieved at the maximum recommended daily dosage, combination therapy or an alternative agent should be considered.', '2', 'Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980):  161-80|Faergeman O "Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin." Acta Med Scand 194 (1973):  165-7|Cohen MI, Winslow PR, Boley SJ "Intestinal obstruction associated with cholestyramine therapy." N Engl J Med 280 (1969):  1285-6|LaRosa J "Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels." Cardiology 76 (1989):  55-61;|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39566, 25528, 'Cholestyramine', 'Constipation', 'The use of bile acid sequestrants may produce or worsen preexisting constipation.  Constipation associated with these agents may aggravate hemorrhoids.  Therapy with bile acid sequestrants should be administered cautiously in patients with preexisting constipation, hemorrhoids, or symptomatic coronary artery disease.  The dosage should be increased very gradually according to manufacturer guidelines to minimize the risk of fecal impaction, and patients should be encouraged to increase fluid and fiber intake.  Occasional use of a stool softener may also be indicated.  If constipation worsens or develops during therapy, or the desired therapeutic response is not achieved at the maximum recommended daily dosage, combination therapy or an alternative agent should be considered.', '2', 'Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980):  161-80|Faergeman O "Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin." Acta Med Scand 194 (1973):  165-7|Cohen MI, Winslow PR, Boley SJ "Intestinal obstruction associated with cholestyramine therapy." N Engl J Med 280 (1969):  1285-6|LaRosa J "Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels." Cardiology 76 (1989):  55-61;|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39567, 25538, 'Cholestyramine', 'Constipation', 'The use of bile acid sequestrants may produce or worsen preexisting constipation.  Constipation associated with these agents may aggravate hemorrhoids.  Therapy with bile acid sequestrants should be administered cautiously in patients with preexisting constipation, hemorrhoids, or symptomatic coronary artery disease.  The dosage should be increased very gradually according to manufacturer guidelines to minimize the risk of fecal impaction, and patients should be encouraged to increase fluid and fiber intake.  Occasional use of a stool softener may also be indicated.  If constipation worsens or develops during therapy, or the desired therapeutic response is not achieved at the maximum recommended daily dosage, combination therapy or an alternative agent should be considered.', '2', 'Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980):  161-80|Faergeman O "Effects and side-effects of treatment of hypercholesterolemia with cholestyramine and neomycin." Acta Med Scand 194 (1973):  165-7|Cohen MI, Winslow PR, Boley SJ "Intestinal obstruction associated with cholestyramine therapy." N Engl J Med 280 (1969):  1285-6|LaRosa J "Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels." Cardiology 76 (1989):  55-61;|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39568, 2520, 'Cholestyramine', 'Acidosis', 'Bile acid sequestrants are chloride forms of anion exchange resins and may produce hyperchloremic acidosis with chronic use.  Therapy with bile acid sequestrants should be administered cautiously in patients who may be particularly susceptible, including children or smaller patients and patients with renal impairment or volume depletion.', '2', 'Scheel PJ Jr, Whelton A, Rossiter K, Watson A "Cholestyramine-induced hyperchloremic metabolic acidosis." J Clin Pharmacol 32 (1992):  536-8|Hartline JV "Letter: Hyperchloremia, metabolic acidosis, and cholestyramine." J Pediatr 89 (1976):  155|Kleinman PK "Letter: Cholestyramine and metabolic acidosis." N Engl J Med 290 (1974):  861|Clouston WM, Lloyd HM "Cholestyramine induced hyperchloremic metabolic acidosis ." Aust N Z J Med 15 (1985):  271|Eaves ER, Korman MG "Cholestyramine induced hyperchloremic metabolic acidosis." Aust N Z J Med 14 (1984):  670-2|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39569, 25528, 'Cholestyramine', 'Acidosis', 'Bile acid sequestrants are chloride forms of anion exchange resins and may produce hyperchloremic acidosis with chronic use.  Therapy with bile acid sequestrants should be administered cautiously in patients who may be particularly susceptible, including children or smaller patients and patients with renal impairment or volume depletion.', '2', 'Scheel PJ Jr, Whelton A, Rossiter K, Watson A "Cholestyramine-induced hyperchloremic metabolic acidosis." J Clin Pharmacol 32 (1992):  536-8|Hartline JV "Letter: Hyperchloremia, metabolic acidosis, and cholestyramine." J Pediatr 89 (1976):  155|Kleinman PK "Letter: Cholestyramine and metabolic acidosis." N Engl J Med 290 (1974):  861|Clouston WM, Lloyd HM "Cholestyramine induced hyperchloremic metabolic acidosis ." Aust N Z J Med 15 (1985):  271|Eaves ER, Korman MG "Cholestyramine induced hyperchloremic metabolic acidosis." Aust N Z J Med 14 (1984):  670-2|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39570, 25538, 'Cholestyramine', 'Acidosis', 'Bile acid sequestrants are chloride forms of anion exchange resins and may produce hyperchloremic acidosis with chronic use.  Therapy with bile acid sequestrants should be administered cautiously in patients who may be particularly susceptible, including children or smaller patients and patients with renal impairment or volume depletion.', '2', 'Scheel PJ Jr, Whelton A, Rossiter K, Watson A "Cholestyramine-induced hyperchloremic metabolic acidosis." J Clin Pharmacol 32 (1992):  536-8|Hartline JV "Letter: Hyperchloremia, metabolic acidosis, and cholestyramine." J Pediatr 89 (1976):  155|Kleinman PK "Letter: Cholestyramine and metabolic acidosis." N Engl J Med 290 (1974):  861|Clouston WM, Lloyd HM "Cholestyramine induced hyperchloremic metabolic acidosis ." Aust N Z J Med 15 (1985):  271|Eaves ER, Korman MG "Cholestyramine induced hyperchloremic metabolic acidosis." Aust N Z J Med 14 (1984):  670-2|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39571, 2520, 'Cholestyramine', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', '"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn|"Product Information. Questran Light (cholestyramine)." Bristol-Myers Squibb  (2001):|"Product Information. Welchol (colesevelam)." Daiichi Sankyo, Inc.  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39572, 25528, 'Cholestyramine', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', '"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn|"Product Information. Questran Light (cholestyramine)." Bristol-Myers Squibb  (2001):|"Product Information. Welchol (colesevelam)." Daiichi Sankyo, Inc.  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39573, 25538, 'Cholestyramine', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', '"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn|"Product Information. Questran Light (cholestyramine)." Bristol-Myers Squibb  (2001):|"Product Information. Welchol (colesevelam)." Daiichi Sankyo, Inc.  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39574, 2520, 'Cholestyramine', 'Nutrition disorder', 'Bile acid sequestrants may interfere with the absorption of folic acid and fat soluble vitamins such as A, D, and K.  Chronic use of bile acid sequestrants may cause increased bleeding tendency due to hypoprothrombinemia associated with vitamin K deficiency.  Anemia may also occur due to reduced serum or red blood cell folate.  Supplementation with oral vitamins and/or folate should be considered during prolonged therapy with bile acid sequestrants, particularly in patients with preexisting vitamin and/or folate deficiencies, anemia, or a bleeding diathesis.', '2', 'Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980):  161-80|Gross L, Brotman M "Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy." Ann Intern Med 72 (1970):  95-6|Heaton KW, Lever JV, Barnard D "Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea." Gastroenterology 62 (1972):  642-6|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39575, 25528, 'Cholestyramine', 'Nutrition disorder', 'Bile acid sequestrants may interfere with the absorption of folic acid and fat soluble vitamins such as A, D, and K.  Chronic use of bile acid sequestrants may cause increased bleeding tendency due to hypoprothrombinemia associated with vitamin K deficiency.  Anemia may also occur due to reduced serum or red blood cell folate.  Supplementation with oral vitamins and/or folate should be considered during prolonged therapy with bile acid sequestrants, particularly in patients with preexisting vitamin and/or folate deficiencies, anemia, or a bleeding diathesis.', '2', 'Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980):  161-80|Gross L, Brotman M "Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy." Ann Intern Med 72 (1970):  95-6|Heaton KW, Lever JV, Barnard D "Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea." Gastroenterology 62 (1972):  642-6|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39576, 25538, 'Cholestyramine', 'Nutrition disorder', 'Bile acid sequestrants may interfere with the absorption of folic acid and fat soluble vitamins such as A, D, and K.  Chronic use of bile acid sequestrants may cause increased bleeding tendency due to hypoprothrombinemia associated with vitamin K deficiency.  Anemia may also occur due to reduced serum or red blood cell folate.  Supplementation with oral vitamins and/or folate should be considered during prolonged therapy with bile acid sequestrants, particularly in patients with preexisting vitamin and/or folate deficiencies, anemia, or a bleeding diathesis.', '2', 'Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980):  161-80|Gross L, Brotman M "Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy." Ann Intern Med 72 (1970):  95-6|Heaton KW, Lever JV, Barnard D "Osteomalacia associated with cholestyramine therapy for postileectomy diarrhea." Gastroenterology 62 (1972):  642-6|"Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc  (2002):|"Product Information. Colestid (colestipol)." Pharmacia and Upjohn', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39577, 274, 'Cinacalcet', 'Hypocalcemia', 'Cinacalcet lowers serum calcium, and therefore patients should be carefully monitored for the occurrence of hypocalcemia.  Potential manifestations of hypocalcemia include paresthesias, myalgias, cramping, tetany, and convulsions.  Cinacalcet treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).  Monitor serum calcium 1 week after treatment initiation or dose adjustment, and once every month once the maintenance dose has been established.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39578, 2595, 'Cinacalcet', 'Hypocalcemia', 'Cinacalcet lowers serum calcium, and therefore patients should be carefully monitored for the occurrence of hypocalcemia.  Potential manifestations of hypocalcemia include paresthesias, myalgias, cramping, tetany, and convulsions.  Cinacalcet treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).  Monitor serum calcium 1 week after treatment initiation or dose adjustment, and once every month once the maintenance dose has been established.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39579, 8182, 'Cinacalcet', 'Hypocalcemia', 'Cinacalcet lowers serum calcium, and therefore patients should be carefully monitored for the occurrence of hypocalcemia.  Potential manifestations of hypocalcemia include paresthesias, myalgias, cramping, tetany, and convulsions.  Cinacalcet treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).  Monitor serum calcium 1 week after treatment initiation or dose adjustment, and once every month once the maintenance dose has been established.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39580, 8183, 'Cinacalcet', 'Hypocalcemia', 'Cinacalcet lowers serum calcium, and therefore patients should be carefully monitored for the occurrence of hypocalcemia.  Potential manifestations of hypocalcemia include paresthesias, myalgias, cramping, tetany, and convulsions.  Cinacalcet treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).  Monitor serum calcium 1 week after treatment initiation or dose adjustment, and once every month once the maintenance dose has been established.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39581, 16337, 'Cinacalcet', 'Hypocalcemia', 'Cinacalcet lowers serum calcium, and therefore patients should be carefully monitored for the occurrence of hypocalcemia.  Potential manifestations of hypocalcemia include paresthesias, myalgias, cramping, tetany, and convulsions.  Cinacalcet treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).  Monitor serum calcium 1 week after treatment initiation or dose adjustment, and once every month once the maintenance dose has been established.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39582, 24549, 'Cinacalcet', 'Hypocalcemia', 'Cinacalcet lowers serum calcium, and therefore patients should be carefully monitored for the occurrence of hypocalcemia.  Potential manifestations of hypocalcemia include paresthesias, myalgias, cramping, tetany, and convulsions.  Cinacalcet treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).  Monitor serum calcium 1 week after treatment initiation or dose adjustment, and once every month once the maintenance dose has been established.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39583, 24550, 'Cinacalcet', 'Hypocalcemia', 'Cinacalcet lowers serum calcium, and therefore patients should be carefully monitored for the occurrence of hypocalcemia.  Potential manifestations of hypocalcemia include paresthesias, myalgias, cramping, tetany, and convulsions.  Cinacalcet treatment should not be initiated if serum calcium is less than the lower limit of the normal range (8.4 mg/dL).  Monitor serum calcium 1 week after treatment initiation or dose adjustment, and once every month once the maintenance dose has been established.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39584, 274, 'Cinacalcet', 'Hypotension', 'Postmarketing safety surveillance studies have reported cases of hypotension, worsening heart failure and/or arrhythmias in patients with impaired cardiac function receiving cinacalcet.  A causal relationship could not been excluded and this may be mediated by reductions in serum calcium.  Cinacalcet should be used with caution in patients with hypotension or preexisting impaired cardiac function.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39585, 2595, 'Cinacalcet', 'Hypotension', 'Postmarketing safety surveillance studies have reported cases of hypotension, worsening heart failure and/or arrhythmias in patients with impaired cardiac function receiving cinacalcet.  A causal relationship could not been excluded and this may be mediated by reductions in serum calcium.  Cinacalcet should be used with caution in patients with hypotension or preexisting impaired cardiac function.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39586, 8182, 'Cinacalcet', 'Hypotension', 'Postmarketing safety surveillance studies have reported cases of hypotension, worsening heart failure and/or arrhythmias in patients with impaired cardiac function receiving cinacalcet.  A causal relationship could not been excluded and this may be mediated by reductions in serum calcium.  Cinacalcet should be used with caution in patients with hypotension or preexisting impaired cardiac function.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39587, 8183, 'Cinacalcet', 'Hypotension', 'Postmarketing safety surveillance studies have reported cases of hypotension, worsening heart failure and/or arrhythmias in patients with impaired cardiac function receiving cinacalcet.  A causal relationship could not been excluded and this may be mediated by reductions in serum calcium.  Cinacalcet should be used with caution in patients with hypotension or preexisting impaired cardiac function.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39588, 16337, 'Cinacalcet', 'Hypotension', 'Postmarketing safety surveillance studies have reported cases of hypotension, worsening heart failure and/or arrhythmias in patients with impaired cardiac function receiving cinacalcet.  A causal relationship could not been excluded and this may be mediated by reductions in serum calcium.  Cinacalcet should be used with caution in patients with hypotension or preexisting impaired cardiac function.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39589, 24549, 'Cinacalcet', 'Hypotension', 'Postmarketing safety surveillance studies have reported cases of hypotension, worsening heart failure and/or arrhythmias in patients with impaired cardiac function receiving cinacalcet.  A causal relationship could not been excluded and this may be mediated by reductions in serum calcium.  Cinacalcet should be used with caution in patients with hypotension or preexisting impaired cardiac function.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39590, 24550, 'Cinacalcet', 'Hypotension', 'Postmarketing safety surveillance studies have reported cases of hypotension, worsening heart failure and/or arrhythmias in patients with impaired cardiac function receiving cinacalcet.  A causal relationship could not been excluded and this may be mediated by reductions in serum calcium.  Cinacalcet should be used with caution in patients with hypotension or preexisting impaired cardiac function.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39591, 274, 'Cinacalcet', 'Seizures', 'Cinacalcet may lower seizure threshold in patients with a history of seizures.  Serum calcium levels should be closely monitored in patients receiving cinacalcet, particularly in patients with history of seizure disorders.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39592, 2595, 'Cinacalcet', 'Seizures', 'Cinacalcet may lower seizure threshold in patients with a history of seizures.  Serum calcium levels should be closely monitored in patients receiving cinacalcet, particularly in patients with history of seizure disorders.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39593, 8182, 'Cinacalcet', 'Seizures', 'Cinacalcet may lower seizure threshold in patients with a history of seizures.  Serum calcium levels should be closely monitored in patients receiving cinacalcet, particularly in patients with history of seizure disorders.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39594, 8183, 'Cinacalcet', 'Seizures', 'Cinacalcet may lower seizure threshold in patients with a history of seizures.  Serum calcium levels should be closely monitored in patients receiving cinacalcet, particularly in patients with history of seizure disorders.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39595, 16337, 'Cinacalcet', 'Seizures', 'Cinacalcet may lower seizure threshold in patients with a history of seizures.  Serum calcium levels should be closely monitored in patients receiving cinacalcet, particularly in patients with history of seizure disorders.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39596, 24549, 'Cinacalcet', 'Seizures', 'Cinacalcet may lower seizure threshold in patients with a history of seizures.  Serum calcium levels should be closely monitored in patients receiving cinacalcet, particularly in patients with history of seizure disorders.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39597, 24550, 'Cinacalcet', 'Seizures', 'Cinacalcet may lower seizure threshold in patients with a history of seizures.  Serum calcium levels should be closely monitored in patients receiving cinacalcet, particularly in patients with history of seizure disorders.', '2', '"Product Information. Sensipar (cinacalcet)." Amgen USA  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39598, 23011, 'Cisapride', 'Heart Diseases', 'The use of cisapride is contraindicated in patients with cardiac disease.  Serious cardiac arrhythmias, including ventricular arrhythmias and torsades de pointes associated with QT prolongation have been rarely associated with the use of cisapride, especially when taken in conjunction with other medications known to prolong the QT interval.', '3', '"Product Information. Propulsid (cisapride)." Janssen Pharmaceuticals  (2001):|Ahmad SR, Wolfe SM "Cisapride and torsades de pointes." Lancet 345 (1995):  508|Bran S, Murray WA, Hirsch IB, Palmer JP "Long QT syndrome during high-dose cisapride." Arch Intern Med 155 (1995):  765-8|Lewin MB, Bryant RM, Fenrich AL, Grifka RG "Cisapride-induced long QT interval." J Pediatr 128 (1996):  279-81|Wysowski DK, Bacsanyi J "Cisapride and fatal arrhythmia." N Engl J Med 335 (1996):  290-1|Bennett JR "How safe and acceptable is cisapride?" Scand J Gastroenterol Suppl 165 (1989):  59-61|Wysowski DK "Cisapride and fatal arrhythmia." N Engl J Med 335 (1996):  290-1|Bedu A, Lupoglazoff JM, Faure C, Denjoy I, Casasoprana A, Aujard Y "Cisapride high dosage and long QT interval." J Pediatr 130 (1997):  164|Grifka RG "Cisapride high dosage and long QT interval - reply." J Pediatr 130 (1997):  164|Hanson R, Browne G, Fasher B, Mcaskill M, Moroney P, Hawker R "Cisapride-induced prolonged QT interval: too much of a good thing!." J Pediatr 130 (1997):  164-6|Gunasekaran TS, DuBrow I "Cisapride-induced long QT interval: What is the role of ranitidine?" J Pediatr 130 (1997):  679-80|Grifka R, Lewin M "Cisapride-induced long QT interval: What is the role of ranitidine? - Reply." J Pediatr 130 (1997):  680|Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI "Proarrhythmia associated with cisapride in children." Pediatrics 101 (1998):  1053-6|Gray VS "Syncopal episodes associated with cisapride and concurrent drugs." Ann Pharmacother 32 (1998):  648-51|Ault A "US FDA warns doctors to use cisapride as last resort only." Lancet 352 (1998):  120', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39599, 23011, 'Cisapride', 'Gastrointestinal Diseases', 'The use of cisapride is contraindicated in patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation.  Enhanced gastrointestinal motility could be harmful in these patients.', '3', '"Product Information. Propulsid (cisapride)." Janssen Pharmaceuticals  (2001):|Quigley EMM "The clinical pharmacology of motility disorders - the perils (and pearls) of prokinesia." Gastroenterology 106 (1994):  1112-4', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39600, 24473, 'Chlorpropamide', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39601, 24473, 'Chlorpropamide', 'Diabetic Ketoacidosis', 'The use of some sulfonylurea agents is contraindicated for the treatment of patients with diabetic ketoacidosis, with or without coma.  In addition, these agents should not be used as sole therapy in patients with type I diabetes mellitus.', '3', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39602, 24473, 'Chlorpropamide', 'Liver Diseases', 'Sulfonylureas are metabolized in the liver, and their metabolites (some with pharmacologic activity) are excreted in the urine and feces.  Patients with impaired liver and/or renal function treated with sulfonylureas may be exposed to higher serum drug concentrations, which can increase the potential for severe hypoglycemic episodes induced by these agents.  In the presence of hepatic impairment, gluconeogenic capacity may also be diminished, further compounding the risk.  Therapy with sulfonylureas should be administered cautiously in patients with liver and/or renal disease.  Reduced dosages and longer intervals between dosage adjustments may be required.  Hypoglycemia, if it occurs during treatment, may be prolonged in these patients because of slowed metabolism and/or excretion of the drugs.', '3', 'Johnson PC, Hennes AR, Driscoll T, West KM "Metabolic fate of chlorpropamide in man." Ann N Y Acad Sci 74 (1959):  459-72|Brotherton PM, Grieveson P, McMartin C "A study of the metabolic fate of chlorpropamide in man." Clin Pharmacol Ther 10 (1970):  505-14|Petitpierre B, Perrin L, Rudhardt M, et al. "Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy." Int J Clin Pharmacol 6 (1972):  120-4|Huupponen R, Lammintausta R "Chlorpropamide bioavailability and pharmacokinetics." Int J Clin Pharmacol Ther Toxicol 19 (1981):  331-3|Neuvonen PJ, Karkkainen S, Lehtovaara R "Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination." Eur J Clin Pharmacol 32 (1987):  297-301|"Glibenclamide: a review." Drugs 1 (1971):  116-40|Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Albert KS, Welling PG "Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function." Clin Pharmacol Ther 39 (1986):  318-24|Sartor G, Melander A, Schersten B, Wahlin-Boll E "Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers." Acta Med Scand 208 (1980):  301-7|Prendergast BD "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents." Clin Pharm 3 (1984):  473-85|Kobayashi KA, Bauer LA, Horn JR, Opheim K, Wood F, Jr  Kradjan WA "Glipizide pharmacokinetics in young and elderly volunteers." Clin Pharm 7 (1988):  224-8|Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J "Pharmacokinetics of glipizide in man: influence of renal insufficiency." Diabetologia Sep (1973):  331-8|Pentikainen PJ, Neuvonen PJ, Penttila A "Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers." Int J Clin Pharmacol Ther Toxicol 21 (1983):  98-107|Lebovitz HE "Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use." Pharmacotherapy 5 (1985):  63-77|"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|Rydberg T, Jonsson A, Roder M, Melander A "Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans." Diabetes Care 17 (1994):  1026-30|Rydberg T, Jonsson A, Melander A "Comparison of the kinetics of glyburide and its active metabolites in humans." J Clin Pharm Ther 20 (1995):  283-95|Badian M, Korn A, Lehr KH, Malerczyk V, Waldhausl W "Determination of the absolute bioavailability of glimepiride (HOE 490), a new sulphonylurea." Int J Clin Pharmacol Ther Toxicol 30 (1992):  481-2|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39603, 24473, 'Chlorpropamide', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.|"Product Information. Glucophage (metformin)." Bristol-Myers Squibb  (2001):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):|"Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals  (2001):|"Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc  (2022):|"Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals  (2001):|"Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals  (2004):|"Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc  (2005):|"Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39604, 24473, 'Chlorpropamide', 'Glucosephosphate Dehydrogenase Deficiency', 'Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency.  Therapy with these agents should be used with caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative.  There have been postmarketing reports of hemolytic anemia in patients receiving these drugs who did not have known G6PD deficiency.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39605, 24473, 'Chlorpropamide', 'Hyponatremia', 'Treatment with sulfonylureas may cause hyponatremia, in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone.  The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain sulfonylureas and these drugs may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.|"Product Information. Micronase (glyburide)." Pharmacia and Upjohn  (2002):|"Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel  (2001):|"Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn  (2001):|"Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn  (2001):|"Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39606, 2665, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39607, 2666, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39608, 2667, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39609, 2668, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39610, 11914, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39611, 16407, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39612, 16408, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39613, 16412, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39614, 16413, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39615, 16414, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39616, 17037, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39617, 17038, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39618, 24994, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39619, 28757, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39620, 28758, 'Cisplatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39621, 2665, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39622, 2666, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39623, 2667, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39624, 2668, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39625, 11914, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39626, 16407, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39627, 16408, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39628, 16412, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39629, 16413, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39630, 16414, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39631, 17037, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39632, 17038, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39633, 24994, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39634, 28757, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39635, 28758, 'Cisplatin', 'Hearing Loss', 'Cisplatin injection can cause ototoxicity, which is cumulative and may be severe.  Consider audiometric and vestibular function monitoring.  Ototoxicity can occur during or after treatment and can be unilateral or bilateral.  Deafness after the initial dose of cisplatin injection has been reported.  Vestibular toxicity has also been reported.  Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age.  The prevalence of hearing loss in pediatric patients is estimated to be 40-60%.  Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.  Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39636, 2665, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39637, 2666, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39638, 2667, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39639, 2668, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39640, 11914, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39641, 16407, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39642, 16408, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39643, 16412, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39644, 16413, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39645, 16414, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39646, 17037, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39647, 17038, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39648, 24994, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39649, 28757, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39650, 28758, 'Cisplatin', 'Bone Marrow Failure Disorders', 'Myelosuppression has been reported in 25% to 30% of patients administered cisplatin.  Fever and infection have been reported in patients with neutropenia.  Potential fatalities due to infection (secondary to myelosuppression) have been reported.  Therapy with cisplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39651, 2665, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39652, 2666, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39653, 2667, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39654, 2668, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39655, 11914, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39656, 16407, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39657, 16408, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39658, 16412, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39659, 16413, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39660, 16414, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39661, 17037, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39662, 17038, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39663, 24994, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39664, 28757, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39665, 28758, 'Cisplatin', 'Peripheral Nervous System Diseases', 'Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug.  Neurologic symptoms have been reported to occur after a single dose.  Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection.  Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation.  The neuropathy may progress further even after stopping treatment.  Peripheral neuropathy may be irreversible in some patients.  Therapy with cisplatin should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39666, 2665, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39667, 2666, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39668, 2667, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39669, 2668, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39670, 11914, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39671, 16407, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39672, 16408, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39673, 16412, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39674, 16413, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39675, 16414, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39676, 17037, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39677, 17038, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39678, 24994, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39679, 28757, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39680, 28758, 'Cisplatin', 'Kidney Diseases', 'Patients with baseline renal impairment may be more susceptible to cisplatin nephrotoxicity.  Ensure adequate hydration before, during, and after cisplatin injection administration.  Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated.  Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines', '3', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39681, 2665, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39682, 2666, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39683, 2667, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39684, 2668, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39685, 11914, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39686, 16407, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39687, 16408, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39688, 16412, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39689, 16413, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39690, 16414, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39691, 17037, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39692, 17038, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39693, 24994, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39694, 28757, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39695, 28758, 'Cisplatin', 'Anemia, Hemolytic', 'A (+) Coombs'' hemolytic anemia has been reported with the use of cisplatin.  Subsequent therapy may result in increased hemolysis.  If need outweighs the risk, extreme caution should be exercised in administering cisplatin.  Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine.  Therapy with cisplatin should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes.  Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39696, 2665, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39697, 2666, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39698, 2667, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39699, 2668, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39700, 11914, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39701, 16407, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39702, 16408, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39703, 16412, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39704, 16413, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39705, 16414, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39706, 17037, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39707, 17038, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39708, 24994, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39709, 28757, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39710, 28758, 'Cisplatin', 'Toxic Optic Neuropathy', 'Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection.  Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection.  Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.  Caution is advised in patients with visual disabilities.', '2', '"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39711, 2590, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39712, 2621, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39713, 2622, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39714, 2624, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39715, 2626, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39716, 2627, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39717, 2628, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39718, 2630, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39719, 2631, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39720, 2632, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39721, 2633, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39722, 2638, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39723, 2639, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39724, 2640, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39725, 2642, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39726, 2643, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39727, 2644, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39728, 2647, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39729, 2649, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39730, 2650, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39731, 2651, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39732, 2652, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39733, 2653, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39734, 2654, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39735, 2657, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39736, 4081, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39737, 8164, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39738, 10377, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39739, 10378, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39740, 10379, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39741, 11908, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39742, 13099, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39743, 14349, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39744, 14876, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39745, 14877, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39746, 15492, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39747, 16363, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39748, 16367, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39749, 16373, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39750, 16376, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39751, 16379, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39752, 16383, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39753, 16384, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39754, 16388, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39755, 16389, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39756, 16391, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39757, 16398, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39758, 16399, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39759, 16402, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39760, 18192, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39761, 18194, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39762, 20298, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39763, 20299, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39764, 20300, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39765, 20427, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39766, 21255, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39767, 21429, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39768, 22588, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39769, 22740, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39770, 25055, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39771, 25555, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39772, 25682, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39773, 25684, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39774, 26237, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39775, 28683, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39776, 32068, 'Ciprofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39777, 2590, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39778, 2621, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39779, 2622, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39780, 2624, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39781, 2626, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39782, 2627, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39783, 2628, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39784, 2630, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39785, 2631, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39786, 2632, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39787, 2633, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39788, 2638, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39789, 2639, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39790, 2640, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39791, 2642, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39792, 2643, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39793, 2644, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39794, 2647, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39795, 2649, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39796, 2650, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39797, 2651, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39798, 2652, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39799, 2653, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39800, 2654, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39801, 2657, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39802, 4081, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39803, 8164, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39804, 10377, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39805, 10378, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39806, 10379, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39807, 11908, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39808, 13099, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39809, 14349, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39810, 14876, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39811, 14877, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39812, 15492, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39813, 16363, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39814, 16367, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39815, 16373, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39816, 16376, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39817, 16379, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39818, 16383, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39819, 16384, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39820, 16388, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39821, 16389, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39822, 16391, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39823, 16398, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39824, 16399, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39825, 16402, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39826, 18192, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39827, 18194, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39828, 20298, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39829, 20299, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39830, 20300, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39831, 20427, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39832, 21255, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39833, 21429, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39834, 22588, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39835, 22740, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39836, 25055, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39837, 25555, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39838, 25682, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39839, 25684, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39840, 26237, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39841, 28683, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39842, 32068, 'Ciprofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39843, 2590, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39844, 2621, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39845, 2622, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39846, 2624, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39847, 2626, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39848, 2627, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39849, 2628, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39850, 2630, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39851, 2631, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39852, 2632, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39853, 2633, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39854, 2638, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39855, 2639, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39856, 2640, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39857, 2642, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39858, 2643, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39859, 2644, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39860, 2647, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39861, 2649, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39862, 2650, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39863, 2651, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39864, 2652, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39865, 2653, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39866, 2654, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39867, 2657, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39868, 4081, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39869, 8164, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39870, 10377, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39871, 10378, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39872, 10379, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39873, 11908, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39874, 13099, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39875, 14349, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39876, 14876, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39877, 14877, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39878, 15492, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39879, 16363, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39880, 16367, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39881, 16373, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39882, 16376, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39883, 16379, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39884, 16383, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39885, 16384, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39886, 16388, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39887, 16389, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39888, 16391, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39889, 16398, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39890, 16399, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39891, 16402, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39892, 18192, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39893, 18194, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39894, 20298, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39895, 20299, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39896, 20300, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39897, 20427, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39898, 21255, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39899, 21429, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39900, 22588, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39901, 22740, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39902, 25055, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39903, 25555, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39904, 25682, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39905, 25684, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39906, 26237, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39907, 28683, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39908, 32068, 'Ciprofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39909, 2590, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39910, 2621, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39911, 2622, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39912, 2624, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39913, 2626, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39914, 2627, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39915, 2628, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39916, 2630, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39917, 2631, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39918, 2632, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39919, 2633, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39920, 2638, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39921, 2639, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39922, 2640, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39923, 2642, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39924, 2643, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39925, 2644, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39926, 2647, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39927, 2649, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39928, 2650, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39929, 2651, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39930, 2652, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39931, 2653, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39932, 2654, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39933, 2657, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39934, 4081, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39935, 8164, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39936, 10377, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39937, 10378, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39938, 10379, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39939, 11908, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39940, 13099, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39941, 14349, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39942, 14876, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39943, 14877, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39944, 15492, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39945, 16363, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39946, 16367, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39947, 16373, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39948, 16376, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39949, 16379, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39950, 16383, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39951, 16384, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39952, 16388, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39953, 16389, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39954, 16391, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39955, 16398, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39956, 16399, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39957, 16402, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39958, 18192, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39959, 18194, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39960, 20298, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39961, 20299, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39962, 20300, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39963, 20427, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39964, 21255, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39965, 21429, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39966, 22588, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39967, 22740, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39968, 25055, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39969, 25555, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39970, 25682, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39971, 25684, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39972, 26237, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39973, 28683, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39974, 32068, 'Ciprofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39975, 2590, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39976, 2621, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39977, 2622, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39978, 2624, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39979, 2626, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39980, 2627, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39981, 2628, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39982, 2630, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39983, 2631, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39984, 2632, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39985, 2633, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39986, 2638, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39987, 2639, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39988, 2640, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39989, 2642, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39990, 2643, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39991, 2644, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39992, 2647, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39993, 2649, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39994, 2650, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39995, 2651, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39996, 2652, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39997, 2653, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39998, 2654, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39999, 2657, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40000, 4081, 'Ciprofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);